Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor 2 Positive Carcinoma of Breast”

948 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 948 results

Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Not applicableUnknownNCT05656079
What this trial is testing

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Who this might be right for
Breast Cancer
Shanghai Pudong Hospital 204
Testing effectiveness (Phase 2)Ended earlyNCT02379585
What this trial is testing

Fasting on Newly Diagnosed Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Western Regional Medical Center 8
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)UnknownNCT04318223
What this trial is testing

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
Consorzio Oncotech 168
Testing effectiveness (Phase 2)UnknownNCT04034589
What this trial is testing

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Early research (Phase 1)Ended earlyNCT02095210
What this trial is testing

HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025

Who this might be right for
HER2-positive Breast Cancer
Dorte Nielsen 2
Not applicableNot Yet RecruitingNCT07593196
What this trial is testing

HER2-positive Metastatic Breast Cancer in Kazakhstan

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 240
Testing effectiveness (Phase 2)Active Not RecruitingNCT05710666
What this trial is testing

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Who this might be right for
HER2-positive Breast Cancer
Cancer Trials Ireland 11
Testing effectiveness (Phase 2)WithdrawnNCT00627627
What this trial is testing

Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
MedImmune LLC 56
Post-approval studies (Phase 4)Looking for participantsNCT06429761
What this trial is testing

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

Who this might be right for
BREAST CANCER
AstraZeneca 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06198751
What this trial is testing

Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 104
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Early research (Phase 1)Study completedNCT00068757
What this trial is testing

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Who this might be right for
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC 23
Not applicableStudy completedNCT03981705
What this trial is testing

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Who this might be right for
TN ER-/PR-/HER2- Breast CancerTriple Negative Breast CancerHER2-positive Breast Cancer+1 more
Masonic Cancer Center, University of Minnesota 8
Testing effectiveness (Phase 2)Study completedNCT02654119
What this trial is testing

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Who this might be right for
HER2 Positive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+4 more
University of Nebraska 20
Large-scale testing (Phase 3)Looking for participantsNCT07615751
What this trial is testing

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 502
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07019337
What this trial is testing

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 100
Testing effectiveness (Phase 2)Study completedNCT01973660
What this trial is testing

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 151
Testing effectiveness (Phase 2)UnknownNCT03698383
What this trial is testing

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Korean Cancer Study Group 15
Load More Results